{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:04:13Z","timestamp":1790157853724,"version":"4.1.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008081","name":"Dystrophic Epidermolysis Bullosa Research Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["NY90\/2-1"],"award-info":[{"award-number":["NY90\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["NY90\/3-2"],"award-info":[{"award-number":["NY90\/3-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Matrix Biology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.matbio.2017.12.010","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T13:30:38Z","timestamp":1513863038000},"page":"330-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Therapies for genetic extracellular matrix diseases of the skin"],"prefix":"10.1016","volume":"71-72","author":[{"given":"Alexander","family":"Nystr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bornert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.matbio.2017.12.010_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nature24154","article-title":"Inflammation: memory beyond immunity","author":"Dai","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.matbio.2017.12.010_bb0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/bs.ctdb.2015.11.033","article-title":"Epithelial skin biology: three decades of developmental biology, a hundred questions answered and a thousand new ones to address","volume":"116","author":"Fuchs","year":"2016","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/bs.ctm.2015.05.003","article-title":"Epidermal basement membrane in health and disease","volume":"76","author":"Has","year":"2015","journal-title":"Curr. Top. Membr."},{"key":"10.1016\/j.matbio.2017.12.010_bb0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.matbio.2016.07.012","article-title":"Cell therapy for basement membrane-linked diseases","volume":"57\u201358","author":"Nystr\u00f6m","year":"2017","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2016.12.009","article-title":"The nature and biology of basement membranes","volume":"57\u201358","author":"Pozzi","year":"2017","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.matbio.2016.08.006","article-title":"Proteomic definitions of basement membrane composition in health and disease","volume":"57\u201358","author":"Randles","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.matbio.2016.07.009","article-title":"Molecular pathology of the basement membrane zone in heritable blistering diseases: the paradigm of epidermolysis bullosa","volume":"57\u201358","author":"Uitto","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0040","article-title":"Marfan syndrome; a connective tissue disease at the crossroads of mechanotransduction, TGF\u03b2 signaling and cell stemness","author":"Ramirez","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0045","article-title":"Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas","author":"F\u00f6ll","year":"2017","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0050","article-title":"Decorin is a devouring proteoglycan: remodeling of intracellular catabolism via autophagy and mitophagy","author":"Buraschi","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2017.04.003","article-title":"The provisional matrix: setting the stage for tissue repair outcomes","volume":"60\u201361","author":"Barker","year":"2017","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0060","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.matbio.2016.07.001","article-title":"Mechanical properties of basement membrane in health and disease","volume":"57\u201358","author":"Miller","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.matbio.2016.08.004","article-title":"The role of biophysical properties of provisional matrix proteins in wound repair","volume":"60\u201361","author":"Chester","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.matbio.2017.03.004","article-title":"Sensing the mechano-chemical properties of the extracellular matrix","volume":"64","author":"Ringer","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2520","article-title":"Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations","volume":"10","author":"Bateman","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.matbio.2017.12.010_bb0080","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1172\/JCI93094","article-title":"Increased intracellular proteolysis reduces disease severity in an ER stress-associated dwarfism","volume":"127","author":"Mullan","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2017.12.010_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.matbio.2017.01.002","article-title":"Stromal microenvironment in type VII collagen-deficient skin: the ground for squamous cell carcinoma development","author":"Guerra","year":"2017","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.matbio.2016.08.005","article-title":"Collagen IV diseases: a focus on the glomerular basement membrane in Alport syndrome","volume":"57\u201358","author":"Cosgrove","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0095","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/ajmg.a.38326","article-title":"Drug discovery and development for rare genetic disorders","volume":"173","author":"Sun","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.matbio.2017.12.010_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13141","article-title":"RNA-based therapies for genodermatoses","volume":"26","author":"Bornert","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/nri1708","article-title":"Regulation of MHC class II gene expression by the class II transactivator","volume":"5","author":"Reith","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"136","key":"10.1016\/j.matbio.2017.12.010_bb0110","first-page":"440","article-title":"Antigen presentation by human dermal fibroblasts: activation of resting T lymphocytes","volume":"1950","author":"Umetsu","year":"1986","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.matbio.2017.12.010_bb0115","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.stem.2012.05.015","article-title":"Mesenchymal stromal cells: new directions","volume":"10","author":"Keating","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.matbio.2017.12.010_bb0120","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1089\/hum.2010.115","article-title":"Bone marrow mesenchymal stem cells: historical overview and concepts","volume":"21","author":"Charbord","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0125","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1073\/pnas.95.3.1142","article-title":"Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesisimperfecta","volume":"95","author":"Pereira","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.matbio.2017.12.010_bb0130","doi-asserted-by":"crossref","first-page":"23373","DOI":"10.1016\/S0021-9258(18)54506-3","article-title":"Transgenic mice that express a mini-gene version of the human gene for type I procollagen (COL1A1) develop a phenotype resembling a lethal form of osteogenesis imperfecta","volume":"266","author":"Khillan","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.matbio.2017.12.010_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0140","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","article-title":"Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta","volume":"97","author":"Horwitz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2017.12.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/8326","article-title":"Osteogenesis imperfecta calls for caution-first letter","volume":"5","author":"Marini","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0150","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2011-12-400085","article-title":"Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms","volume":"120","author":"Otsuru","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2017.12.010_bb0155","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jid.2016.06.609","article-title":"Genotype, clinical course, and therapeutic decision making in 76 infants with severe generalized junctional epidermolysis bullosa","volume":"136","author":"Hammersen","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0160","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0165","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/exd.12014","article-title":"Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls","volume":"21","author":"Tolar","year":"2012","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0170","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jpeds.2015.05.051","article-title":"Reduced toxicity conditioning and allogeneic hematopoietic progenitor cell transplantation for recessive dystrophic epidermolysis bullosa","volume":"167","author":"Geyer","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.matbio.2017.12.010_bb0175","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/mt.2016.199","article-title":"Gene therapy for epidermolysis bullosa: sticky business","volume":"24","author":"Nystr\u00f6m","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0180","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2353\/ajpath.2008.070977","article-title":"Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance","volume":"173","author":"Chino","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0185","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1073\/pnas.1016753108","article-title":"PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia","volume":"108","author":"Tamai","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"194","key":"10.1016\/j.matbio.2017.12.010_bb0190","first-page":"1996","article-title":"Transplanted bone marrow-derived circulating PDGFR\u03b1+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft","volume":"1950","author":"Iinuma","year":"2015","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.matbio.2017.12.010_bb0195","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood-2008-06-161299","article-title":"Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells","volume":"113","author":"Tolar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2017.12.010_bb0200","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(13)61897-8","article-title":"Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix","volume":"382","author":"Tolar","year":"2013","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.matbio.2017.12.010_bb0205","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/mt.2015.58","article-title":"High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa","volume":"23","author":"K\u00fchl","year":"2015","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0210","first-page":"3359","article-title":"Antifibrotic effects of cyclosporine A on TGF-\u03b21-treated lung fibroblasts and lungs from bleomycin-treated mice: role of hypoxia-inducible factor-1\u03b1, FASEB","volume":"31","author":"Yamazaki","year":"2017","journal-title":"J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0215","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.jaad.2016.05.047","article-title":"Segmental stiff skin syndrome (SSS): two additional cases with a positive response to mycophenolate mofetil and physical therapy","volume":"75","author":"Kurtzman","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0220","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(89)91998-3","article-title":"Cyclosporin for dystrophic epidermolysis bullosa","volume":"2","author":"Husz","year":"1989","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.matbio.2017.12.010_bb0225","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0190-9622(08)82040-3","article-title":"Prevention of blisters in dystrophic recessive epidermolysis bullosa with cyclosporine","volume":"29","author":"del R\u00edo","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0230","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/09546634.2013.768327","article-title":"Mycophenolate mofetil: a novel immunosuppressant in the treatment of dystrophic epidermolysis bullosa, a randomized controlled trial","volume":"24","author":"El-Darouti","year":"2013","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.matbio.2017.12.010_bb0235","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3727\/096368913X663569","article-title":"Human cord blood-derived unrestricted somatic stem cells promote wound healing and have therapeutic potential for patients with recessive dystrophic epidermolysis bullosa","volume":"23","author":"Liao","year":"2014","journal-title":"Cell Transplant."},{"key":"10.1016\/j.matbio.2017.12.010_bb0240","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/stem.1966","article-title":"Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa","volume":"33","author":"Liao","year":"2015","journal-title":"Stem Cells Dayt. Ohio."},{"key":"10.1016\/j.matbio.2017.12.010_bb0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/14653249.2010.518609","article-title":"Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder","volume":"13","author":"Alexeev","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.matbio.2017.12.010_bb0250","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/labinvest.2017.85","article-title":"Rapid generation of Col7a1(\u2212\/\u2212) mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells","volume":"97","author":"Webber","year":"2017","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114949","article-title":"Negligible immunogenicity of induced pluripotent stem cells derived from human skin fibroblasts","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.matbio.2017.12.010_bb0260","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood.V110.11.1930.1930","article-title":"Mesenchymal stem cells and fibroblasts have similar immunoregulatory properties in vitro but distinct gene expression profiles: implications for cellular therapy","volume":"110","author":"Haniffa","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.matbio.2017.12.010_bb0265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/14653241003587637","article-title":"Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa","volume":"12","author":"Conget","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1016\/j.matbio.2017.12.010_bb0270","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0275","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0280","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.mt.6300041","article-title":"Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing","volume":"15","author":"Woodley","year":"2007","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0285","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/mt.2009.144","article-title":"Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity","volume":"17","author":"Kern","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0290","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0295","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bjd.12599","article-title":"Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial","volume":"169","author":"Petrof","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0300","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jaad.2013.08.014","article-title":"A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa","volume":"69","author":"Venugopal","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0305","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/jid.2011.85","article-title":"HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa","volume":"131","author":"Nagy","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0310","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jid.2016.02.811","article-title":"Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a self-inactivating COL7A1 retroviral vector","volume":"136","author":"Jack\u00f3w","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0315","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/JID.2015.364","article-title":"Lentiviral engineered fibroblasts expressing codon-optimized COL7A1 restore anchoring fibrils in RDEB","volume":"136","author":"Georgiadis","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0320","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/archderm.136.10.1225","article-title":"Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds","volume":"136","author":"Falabella","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0325","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/jid.2014.118","article-title":"Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa","volume":"134","author":"Kiritsi","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0330","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0092-8674(00)81894-2","article-title":"Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion","volume":"88","author":"Jonkman","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.matbio.2017.12.010_bb0335","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1172\/JCI30465","article-title":"Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3","volume":"117","author":"Pasmooij","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2017.12.010_bb0340","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s00018-017-2468-2","article-title":"Revertant mosaicism in genodermatoses","volume":"74","author":"Lim","year":"2017","journal-title":"Cell. Mol. Life Sci. CMLS."},{"key":"10.1016\/j.matbio.2017.12.010_bb0345","first-page":"167","article-title":"Revertant mosaicism in heritable skin diseases \u2014 mechanisms of natural gene therapy","volume":"14","author":"Pasmooij","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0350","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2009.09118.x","article-title":"Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy","volume":"161","author":"Gostynski","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0355","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/jid.2013.308","article-title":"Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy","volume":"134","author":"Gosty\u0144ski","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0360","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/jid.2013.523","article-title":"Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa","volume":"134","author":"Tolar","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0365","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009342","article-title":"Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa","volume":"6","author":"Umegaki-Arao","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0370","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaad.2013.08.052","article-title":"Successful therapeutic transplantation of revertant skin in epidermolysis bullosa","volume":"70","author":"Gosty\u0144ski","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0375","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0380","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jid.2016.10.038","article-title":"Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells","volume":"137","author":"Bauer","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0385","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.matbio.2017.12.010_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.stemcr.2013.11.001","article-title":"Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa","volume":"2","author":"De Rosa","year":"2014","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.matbio.2017.12.010_bb0395","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jid.2017.03.028","article-title":"Human dermal fibroblast subpopulations display distinct gene signatures related to cell behaviors and matrisome","volume":"137","author":"Nauroy","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.matbio.2017.12.010_bb0405","article-title":"Correction of recessive dystrophic epidermolysis bullosa by transposon-mediated integration of COL7A1 in transplantable patient-derived primary keratinocytes","author":"Latella","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0410","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1039\/C5BM00216H","article-title":"A knot polymer mediated non-viral gene transfection for skin cells","volume":"4","author":"Cutlar","year":"2016","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.matbio.2017.12.010_bb0415","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jconrel.2016.06.014","article-title":"Highly branched poly(\u03b2-amino ester)s for skin gene therapy","volume":"244","author":"Zhou","year":"2016","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.matbio.2017.12.010_bb0420","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600102","article-title":"The transition from linear to highly branched poly(\u03b2-amino ester)s: branching matters for gene delivery","volume":"2","author":"Zhou","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.matbio.2017.12.010_bb0425","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/jid.2010.249","article-title":"Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa","volume":"131","author":"Murauer","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0430","doi-asserted-by":"crossref","first-page":"10259","DOI":"10.1093\/nar\/gkx669","article-title":"An RNA-targeted therapy for dystrophic epidermolysis bullosa","volume":"45","author":"Peking","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.matbio.2017.12.010_bb0435","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.3","article-title":"A gene gun-mediated nonviral RNA trans-splicing strategy for Col7a1 repair","volume":"5","author":"Peking","year":"2016","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.matbio.2017.12.010_bb0440","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/mt.2013.290","article-title":"Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant","volume":"22","author":"Melo","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0445","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009540","article-title":"Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","author":"Sebastiano","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0450","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.19","article-title":"Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes","volume":"5","author":"Chamorro","year":"2016","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.matbio.2017.12.010_bb0455","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jid.2015.11.028","article-title":"Meganuclease-mediated COL7A1 gene correction for recessive dystrophic epidermolysis bullosa","volume":"136","author":"Izmiryan","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0460","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1073\/pnas.1512028113","article-title":"Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa","volume":"113","author":"Shinkuma","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.matbio.2017.12.010_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/npjregenmed.2016.14","article-title":"CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa","volume":"1","author":"Webber","year":"2016","journal-title":"Npj Regen. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0470","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa","volume":"25","author":"Hainzl","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0475","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/bjd.14374","article-title":"Amelioration of junctional epidermolysis bullosa due to exon skipping","volume":"174","author":"Kowalewski","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0480","first-page":"1483","article-title":"Restoration of open reading frame resulting from skipping of an exon with an internal deletion in the COL7A1 gene","volume":"78","author":"Cserhalmi-Friedman","year":"1998","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0485","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.13386","article-title":"Skipped exon in COL7A1 determines the clinical phenotypes of dystrophic epidermolysis bullosa","volume":"172","author":"Toyonaga","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0490","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/mt.2016.92","article-title":"Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy","volume":"24","author":"Bornert","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0495","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.1614775114","article-title":"Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.matbio.2017.12.010_bb0500","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.87","article-title":"Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa","volume":"5","author":"Bremer","year":"2016","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.matbio.2017.12.010_bb0505","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jid.2016.07.029","article-title":"Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model","volume":"136","author":"Turczynski","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0510","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","article-title":"Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients","volume":"126","author":"Goto","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0515","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jid.2016.02.002","article-title":"Collagen VII half-life at the dermal-epidermal junction zone: implications for mechanisms and therapy of genodermatoses","volume":"136","author":"K\u00fchl","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0520","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1242\/jcs.080911","article-title":"Lung-specific loss of the laminin \u03b13 subunit confers resistance to mechanical injury","volume":"124","author":"Urich","year":"2011","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.matbio.2017.12.010_bb0525","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.jid.5701197","article-title":"Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3\u2212\/\u2212 keratinocytes in vitro","volume":"128","author":"Igoucheva","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0530","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm1063","article-title":"Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa","volume":"10","author":"Woodley","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0535","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0540","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa","volume":"133","author":"Woodley","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0545","first-page":"184","article-title":"Commentary: new advances in the development of therapies for treating inherited skin fragility disorders","volume":"23","author":"Kopecki","year":"2015","journal-title":"Wound Pract. Res. J. Aust. Wound Manag. Assoc."},{"key":"10.1016\/j.matbio.2017.12.010_bb0550","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1073\/pnas.1620982114","article-title":"Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity","volume":"114","author":"Baradaran-Heravi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.matbio.2017.12.010_bb0555","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1172\/JCI92707","article-title":"Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients","volume":"127","author":"Woodley","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2017.12.010_bb0560","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.jid.2017.05.011","article-title":"Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa","volume":"137","author":"Atanasova","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0565","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bjd.13945","article-title":"A COL7A1 variant leading to in-frame skipping of exon 15 attenuates disease severity in recessive dystrophic epidermolysis bullosa","volume":"173","author":"Schwieger-Briel","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0570","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nmd.2014.11.011","article-title":"European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene","volume":"25","author":"Haas","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.matbio.2017.12.010_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001593","article-title":"A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays","volume":"11","author":"McElroy","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0580","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/mt.2014.140","article-title":"Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa","volume":"22","author":"Cogan","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0585","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/mt.2014.169","article-title":"Small-molecule therapies for genetic skin fragility","volume":"22","author":"Bruckner-Tuderman","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.matbio.2017.12.010_bb0590","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.matbio.2015.10.002","article-title":"Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept","volume":"48","author":"Gubbiotti","year":"2015","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0595","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ajpath.2014.05.010","article-title":"Instructive roles of extracellular matrix on autophagy","volume":"184","author":"Neill","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0600","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.matbio.2015.08.002","article-title":"Perlecan inhibits autophagy to maintain muscle homeostasis in mouse soleus muscle","volume":"48","author":"Ning","year":"2015","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0605","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1080\/15548627.2016.1231279","article-title":"Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial","volume":"12","author":"Castagnaro","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.matbio.2017.12.010_bb0610","doi-asserted-by":"crossref","first-page":"139194","DOI":"10.1155\/2011\/139194","article-title":"Cyclosporine A in Ullrich congenital muscular dystrophy: long-term results","volume":"2011","author":"Merlini","year":"2011","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.matbio.2017.12.010_bb0615","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.2247","article-title":"Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration","volume":"16","author":"Grumati","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0620","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2011.81","article-title":"The collagen VI-related myopathies: muscle meets its matrix","volume":"7","author":"B\u00f6nnemann","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0625","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2014.185","article-title":"Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity","volume":"134","author":"K\u00fcttner","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0630","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jmedgenet-2017-104555","article-title":"Identification of the first dominant mutation of LAMA5 gene causing a complex multisystem syndrome due to dysfunction of the extracellular matrix","volume":"54","author":"Sampaolo","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.matbio.2017.12.010_bb0635","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.matbio.2015.05.006","article-title":"The extracellular matrix and transforming growth factor-\u03b21: tale of a strained relationship","volume":"47","author":"Hinz","year":"2015","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0640","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0044","article-title":"One integrin to rule them all?","volume":"7","author":"Dietz","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0645","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-\u03b2 signaling in cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer."},{"key":"10.1016\/j.matbio.2017.12.010_bb0650","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.phrs.2016.03.018","article-title":"ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis","volume":"107","author":"Sim\u00f5es","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.matbio.2017.12.010_bb0655","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.matbio.2017.12.010_bb0660","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Pediatric Heart Network Investigators, Atenolol versus losartan in children and young adults with Marfan's syndrome","volume":"371","author":"Lacro","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0665","article-title":"A case of segmental stiff skin syndrome treated with systemic losartan","author":"Maillet-Lebel","year":"2017","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0670","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000488","article-title":"Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome","volume":"2","author":"Loeys","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0675","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaad.2016.01.038","article-title":"Segmental stiff skin syndrome (SSS): a distinct clinical entity","volume":"75","author":"Myers","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0680","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature12614","article-title":"Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma","volume":"503","author":"Gerber","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.matbio.2017.12.010_bb0685","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1172\/JCI68127","article-title":"Collagen VII plays a dual role in wound healing","volume":"123","author":"Nystr\u00f6m","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.matbio.2017.12.010_bb0690","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystr\u00f6m","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0695","doi-asserted-by":"crossref","DOI":"10.1038\/nrd4592","article-title":"Dissecting fibrosis: therapeutic insights from the small-molecule toolbox","volume":"14","author":"Nanthakumar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.matbio.2017.12.010_bb0700","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jid.2016.02.423","article-title":"389 Pirfenidone inhibits RDEB fibrosis and scarring","volume":"136","author":"Cogan","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.matbio.2017.12.010_bb0705","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.resinv.2013.09.002","article-title":"Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis","volume":"52","author":"Arai","year":"2014","journal-title":"Respir. Investig."},{"key":"10.1016\/j.matbio.2017.12.010_bb0710","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJM198010023031402","article-title":"Phenytoin therapy of recessive dystrophic epidermolysis bullosa. Clinical trial and proposed mechanism of action on collagenase","volume":"303","author":"Bauer","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0715","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJM199207163270305","article-title":"Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis bullosa study group","volume":"327","author":"Caldwell-Brown","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.matbio.2017.12.010_bb0720","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1590\/S0102-86502010000500014","article-title":"Profile of wound healing process induced by allantoin","volume":"25","author":"Ara\u00fajo","year":"2010","journal-title":"Acta Cir. Bras."},{"key":"10.1016\/j.matbio.2017.12.010_bb0725","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2015.04.015","article-title":"Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): results of a pilot trial","volume":"73","author":"Fine","year":"2015","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Matrix Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X17304201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0945053X17304201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:02:02Z","timestamp":1760554922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0945053X17304201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":145,"alternative-id":["S0945053X17304201"],"URL":"https:\/\/doi.org\/10.1016\/j.matbio.2017.12.010","relation":{},"ISSN":["0945-053X"],"issn-type":[{"value":"0945-053X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapies for genetic extracellular matrix diseases of the skin","name":"articletitle","label":"Article Title"},{"value":"Matrix Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.matbio.2017.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}